Form 4 for KLRS Kalaris Therapeutics, Inc.
Accepted 2022-08-17 00:00:00 ET · period of report 2022-08-16 · accession 0000899243-22-029045 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2022-08-17 | 2022-08-16 | KLRS | VAN BEEK JEROEN B | Chief Commercial Off | A - Grant | $0.00 | +15.0K | 401.4K | +4% | $0 | |
| 2022-08-17 | 2022-08-16 | KLRS | VAN BEEK JEROEN B | Chief Commercial Off | S - Sale | $8.30 | -15.6K | 386.4K | -4% | -$129.4K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-08-16 | A | A | 15,000 | $0.00 | 401,363 | D | — | — | (F3) The shares reported in this transaction represent RSUs issued under the AlloVir, Inc. 2020 Stock Option and Grant Plan (the "Plan"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. 25% of the RSUs shall vest on August 16, 2023, with the remainder vesting in twelve equal quarterly installments thereafter. |
| 2 | Common | Common Stock | 2022-08-16 | S | D | 15,590 | $8.30 | 386,363 | D | — | — | (F2) The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $8.12 to $8.51. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. |